CAR-T CEOs among the world's highest paid; Bind and Navidea team up on R&D;

@FierceBiotech: Unum hits the gas on next-gen CAR-T tech after banking $65M round. Article | Follow @FierceBiotech

@JohnCFierce: Fun note: Unum CEO Wilson is former deals chief for $NVS. I told him that w/ that background, I was amazed he could talk to anyone in media. | Follow @JohnCFierce

@DamianFierce: Pay $5 million, wait 6 months, make $315 million. Biotech! Report | Follow @DamianFierce

> Among the biggest beneficiaries of the fervor over CAR-T therapies for cancer are the executives at the biotechs developing them. Kite Pharma ($KITE) CEO Arie Belldegrun made $95.2 million in salary and shares last year, making him the 8th highest paid CEO in the world, according to Bloomberg, while Juno Therapeutics ($JUNO) chief Hans Bishop came in at 11th with an $88.2 million pay package. Story

> Bind Therapeutics ($BIND) is working with Navidea Biopharmaceuticals' ($NAVB) Macrophage Therapeutics on cancer R&D, lending out its nanoparticle development platform to craft immune-modulating treatments. News

> Colorado's ARCA biopharma ($ABIO) signed a deal to raise $34 million in a private placement, earmerking the cash to support its late-stage atrial fibrillation drug through an ongoing Phase IIb/III trial. More

Medical Device News

@FierceMedDev: ICYMI yesterday: Finnish headset light therapy via the ear canal cut jet lag time in half in study. Article | Follow @FierceMedDev

@VarunSaxena2: U.K. researchers say earlier diagnoses of bladder cancer needed, especially among women. FierceDiagnostics story | Follow @VarunSaxena2

@EmilyWFierce: After stalling for months, NHS England pledges £190M for new hep C treatments. More | Follow @EmilyWFierce

> Hospira execs called 'shameful' for denying cybersecurity risks posed by their infusion pumps. More

> China-U.S. bridging investor Ally Bridge Group discloses 6 recent med tech investments. Story

Pharma News

@FiercePharma:  India competition body cracks down on GSK, Sanofi. More | Follow @FiercePharma

@EricPFierce:  Patheon was a $1.7B company in its first year as it set out to change the CDMO market. Story | Follow @EricPFierce

@CarlyHFierce:  Teva amps up Mylan stake again, winning agenda rights for upcoming annual meeting. Story | Follow @CarlyHFierce

> Blockbuster-to-be cancer meds outclass other big launches--except Sovaldi and statins. Story

> Big Data study flags 'fairly compelling' link between stomach blockbusters and heart risks. News

Vaccines News

> India competition body cracks down on GSK, Sanofi. Report

> Whistleblowers accuse Merck of withholding info on mumps vaccine. More

> Abivax eyes $49M IPO to advance Cuban-made hep B vaccine. Story

> India, Netherlands partner for vaccines development. Item

> One dose of GlaxoSmithKline's Cervarix may suffice. Article

CRO News

> TFS takes the plunge on a risk-sharing deal for a Parkinson's drug. More

> ContraVir recruits CRO ImageIQ for shingles trial. Item

> WuXi signs on to help ReGenX manufacture gene therapies. Story

> Synexus looks to widen its footprint after $128M PE deal. Article

> INC wants to hear from trial sites on how to improve R&D. Report

Pharma Manufacturing News

> Teva builds its Mylan stake in effort toward becoming generics colossus. Item

> South African regulator eases API oversight rules in face of shortages. Story

> California company buys facility for stem cell manufacturing. More

> South Florida men go to prison for $2.2M Mucinex heist. Story

> Sandoz recalls 1M units of generic Zyrtec made in India. Article

Pharma Asia News

> India to exempt some AIDS, TB drugs, and diagnostics from import taxes. Item

> China part of Opdivo combo trial plans as Nasdaq-listed CBMG buys cancer vaccine. Report

> China's Great Firewall flummoxes European businesses, and others. Story

> Two key Alcon Asia-focused executives fired in regional shakeup. Article

> Samsung Bioepis, Celltrion propel South Korea to front ranks of biosimilar race. More

Suggested Articles

The top dose of Regeneron's COVID-19 antibody lowered virus levels and relieved symptoms more quickly than placebo in non-hospitalized patients.

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.